Offering enhanced deep learning technology, the updated NeuroQuant 5.0 software reportedly bolsters segmentation capabilities for amyloid-related imaging abnormalities (ARIA) in patients with Alzheimer’s disease.
The Food and Drug Administration (FDA) has granted 510(k) clearance for the updated NeuroQuant® 5.0 software, which offers enhanced magnetic resonance imaging (MRI)-based artificial intelligence (AI) capabilities for assessing patients being treated for Alzheimer’s disease and other neurological conditions.
NeuroQuant 5.0 features advanced segmentation and quantification for amyloid-related imaging abnormalities (ARIA) detected on brain MRI scans of patients being treated with anti-amyloid therapies for Alzheimer’s disease, according to Cortechs.ai, the manufacturer of the software.
The newly FDA-cleared NeuroQuant 5.0 software reportedly features advanced segmentation and quantification for amyloid-related imaging abnormalities (ARIA) for patients with Alzheimer’s disease as well as integration of of susceptibility-sensitive MRI sequences that enhance detection of smaller brain lesions, according to Cortechs.ai, the manufacturer of the software. (Image courtesy of Cortechs.ai.)
The company adds that the deep learning capabilities within NeuroQuant 5.0 facilitate improved visualization of lesions associated with traumatic brain injury (TBI), ARIA-E, ARIA-H and cerebral amyloid angiopathy. Another benefit of the NeuroQuant 5.0 software involves the integration of susceptibility-sensitive MRI sequences that enhance detection of smaller brain lesions, according to Cortechs.ai.
"With this release, we are transforming the way radiologists and neurologists approach neurological evaluations, helping to ensure more accurate and timely diagnoses for patients,” noted Kyle Frye, the chief executive officer at Cortechs.ai.
Can Emerging AI Software Offer Detection of CAD on CCTA on Par with Radiologists?
May 14th 2025In a study involving over 1,000 patients who had coronary computed tomography angiography (CCTA) exams, AI software demonstrated a 90 percent AUC for assessments of cases > CAD-RADS 3 and 4A and had a 98 percent NPV for cases > CAD-RADS 4A.